DSpace Repository

The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency

Show simple item record

dc.creator CANATAN, Duran
dc.creator EREN, Erdal
dc.creator OZGUNER, I. Faruk
dc.creator DUMAN, Handan
dc.creator EREN, Cagatay
dc.creator Savas, Cagri
dc.creator Buyukyavuz, Ilker
dc.date 2007-05-31T21:00:00Z
dc.date.accessioned 2020-10-06T10:48:14Z
dc.date.available 2020-10-06T10:48:14Z
dc.identifier 8d987f29-55e6-4479-9fa5-8e290237f6b6
dc.identifier 10.1097/mbc.0b013e3280c60d13
dc.identifier https://avesis.sdu.edu.tr/publication/details/8d987f29-55e6-4479-9fa5-8e290237f6b6/oai
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/66040
dc.description Congenital factor VII deficiency is a rare autosomal recessive hemorrhagic disorder and surgery is normally the cause of excessive bleeding. In this report, we describe the first case with congenital factor VII deficiency admitted to our clinics for the sunnet operation (circumcision), in which recombinant activated factor VII (rFVIIa; NovoSeven) was used to manage the bleeding. The patient was an 8-year old boy with moderate factor VII deficiency (factor VII level, 4%), and rFVIIa was administered at a dose of 20 mu g/kg per dose during the circumcision operation. The same dose was repeated at 2, 4, 6, 9,12,15, 18, 21 and 24 h post operation. The circumcision operation could therefore be safely performed in patients with congenital factor VII using rFVIIa.
dc.language eng
dc.rights info:eu-repo/semantics/closedAccess
dc.title The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency
dc.type info:eu-repo/semantics/article


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account